Abstract Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR) recommended for patients with metastatic renal cell carcinoma (mRCC) who progressed on previous vascular endothelial growth factor (VEGF) receptor-tyrosine kinase inhibitor therapy. Efficacy of everolimus in patients who progressed on anti-VEGF monoclonal antibody bevacizumab is unknown. We did a multicenter prospective trial of everolimus in patients with mRCC whose disease had progressed on bevacizumab ± interferon alpha (IFN). Patients with clear-cell mRCC which had progressed on bevacizumab ± IFN received everolimus 10 mg once daily. The primary end point was the proportion of patients remaining progression-free for 56 days, and a twostage Simon design was used, with 80 % power and an alpha risk of 5 %. This study is registered with ClinicalTrials.gov, number NCT02056587. From December 2011 to October 2013, a total of 37 patients (28 M, 9 F) were enrolled. Median age was 60.5 years (range 41-66), 11 % had Eastern Cooperative Oncology Group Performance Status (ECOG PS) >2, and Memorial Sloan-Kettering Cancer Center (MSKCC) favorable/intermediate risk was 38/62 %. Five (14 %) patients had a confirmed partial response and 26 (70 %) patients had a stable disease. Median progressionfree survival was 11.5 months (95 % CI,. Median overall survival was not reached. No grade 3 or 4 treatmentrelated toxicities were observed. The most common grade 2 adverse events were fatigue (19 %) and pneumonitis (8 %). Everolimus demonstrated a favorable toxicity profile and promising anti-tumor activity as a second-line therapy in metastatic renal cell carcinoma (RCC) patients previously treated with bevacizumab ± IFN.
Introduction
Two tyrosine kinase inhibitors, sunitinib and pazopanib, which target the vascular endothelial growth factor (VEGF) receptor (VEGFR), and bevacizumab, a monoclonal antibody to VEGF, have shown clinical benefit for patients with treatment-naive metastatic renal cell carcinoma (RCC) by prolonging progression-free survival [1] [2] [3] [4] . However, complete or durable responses have been only rarely noted, necessitating chronic therapy for most patients, and treatment has typically been associated with the development of resistance after a median of 8.5-11.1 months. Sequential use of targeted agents has become the standard of care, with activity seen when using a mammalian target of rapamycin (mTOR) inhibitor after progression of disease on a previous VEGFRtargeted therapy.
Everolimus has shown clinical activity in metastatic RCC patients who had received VEGFR tyrosine kinase inhibitors in first or second lines of treatment [5] . Efficacy of everolimus in patients who progressed on anti-VEGF monoclonal antibody bevacizumab is unknown.
The present prospective proof-of-concept study evaluated the use of everolimus in patients previously treated with bevacizumab ± interferon alpha (IFN). In this article, we report the results of this multicenter trial.
Patients and methods

Eligibility
The study population consisted of adults (aged 18 years and above) with metastatic RCC that showed a clear-cell component, which had progressed on or within 6 months of stopping treatment with bevacizumab ± IFN. Key eligibility criteria included the presence of measurable disease (as per the Response Evaluation Criteria in Solid Tumors (RECIST)), favorable or intermediate prognosis according to the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria, adequate renal function: measured or calculated creatinine clearance >60 ml/min, absolute granulocyte count ≥1500/mm 3 , platelets ≥100,000 mm 3 , bilirubin ≤1.5-fold the upper limit of normal, and a signed informed consent. Patients were ineligible if they had previously received mTOR inhibitor therapy (temsirolimus), had untreated CNS metastases, or had uncontrolled medical conditions (e.g., unstable angina pectoris, symptomatic congestive heart failure, recent myocardial infarction, or diabetes).
The staging procedure comprised a CT scan of the thorax, abdomen, and pelvis. A CT scan or magnetic resonance imaging (MRI) of the brain was also to be carried out. A bone scan was also carried out in case of bone-related symptoms.
The trial was approved by the institutional review board and by the ethics committee in each center. The sponsor was the Kidney Cancer Research Bureau, Moscow, Russia, and participating centers included N.N. Blokhin Russian Cancer Research Center, Moscow, Altai Regional Cancer Center, Barnaul, Tatarstan Regional Cancer Center, Kazan, and Primorsky Regional Cancer Center, Vladivostok. All patients provided written informed consent. The authors confirm that this trial is registered.
Treatment
Patients received continuous treatment with oral everolimus 10 mg once daily. Each cycle was considered as 28 days of treatment; safety was assessed every 14 days for the first three cycles and every 4 weeks thereafter.
Doses were delayed or reduced if patients had clinically significant hematological or other adverse events that were deemed to be related to everolimus, according to a nomogram described in the protocol. In such cases, doses were reduced to 5 mg once daily.
Treatment was continued until disease progression, unacceptable toxicity, death, or discontinuation for any other reason.
Evaluation and biostatistics analysis
All patients were assessable for efficacy (intention-to-treat analysis). Tumor measurements (assessed by CT or MRI scans) were done at screening and were subsequently repeated every 56 days for the remainder of the study, as well as on discontinuation of study drug. Additional scans were done as warranted to confirm response (no sooner than 4 weeks and no later than 6 weeks after its initial observation), or whenever disease progression was suspected.
All patients who received at least one dose of study drug and had follow-up were assessed for safety. Safety assessments consisted of monitoring and recording of all adverse events, regular monitoring of hematology and clinical chemistry measurements (laboratory evaluations), regular measurement of vital signs, performance of physical examinations, and recording of all concomitant medications and therapies. Adverse events and laboratory abnormalities were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0.
Based on results of previous studies evaluating efficacy of everolimus in patients with metastatic RCC who progressed on VEGFR-targeted therapy [5] , the primary end point was the proportion of patients remaining progression-free for 56 days, and a two-stage Simon design was used, with 80 % power and an alpha risk of 5 %. The first step was to include 23 patients with the intention of continuing accrual if more than 13 patients were without progression of disease. The total number of patients to be accrued on to the trial was 37, and the hypothesis was to detect at least 24 patients with no evidence of disease progression.
Survival times were calculated from the date of therapy initiation to the date of progression or death (progression-free survival) and the date of death (overall survival). Survival curves were estimated using the Kaplan-Meier method.
Results
From December 2011 to October 2013, 37 patients were accrued. Baseline demographic and disease characteristics are summarized in Table 1 
Response
During the first step of this trial, 19 of 23 patients achieved a partial response (N=3) or stable disease (N=16), and patient accrual was therefore continued as previously decided. After completion of the total planned accrual of 37 patients, disease control rate was 84 % (N=31). Confirmed objective tumor responses (all partial responses) were seen in five (14 %) patients. Twenty-six (70 %) patients had a stable disease. Median time to response was 100.8 days.
One patient had a partial response for the maximal treatment period of 1.5 years. This patient then stopped therapy, had a relapse 2 months later, and is currently having a second partial response after retreatment under a compassionate exemption.
Survival
The median follow-up was 14 (7-21) months and 20 progressions have occurred. Median progression-free survival was 11.5 months (95 % CI 8.8-14.2). Progression-free survival curve is shown in Fig. 1 . At the time of analysis, 29 patients (78 %) were alive, and median overall survival had not been reached. The 1-year overall survival rate was 81 %.
Toxicity
No unexpected toxicity was observed. The most common grade 2 adverse events were fatigue (19 %) and non-infectious pneumonitis (8 %). None of the treated patients experienced infections. Of the 37 patients, one patient discontinued everolimus therapy on their own accord due to relapse of systemic lupus erythematosus and one patient had 14-day interruption of an everolimus therapy due to grade 3 hyperglycemia. No grade 4 treatment-related toxicity was found. 
Discussion
In 2012, 525,,931 new cases of cancer were registered in Russia [6] . RCC comprises approximately 4.3 % of all malignancies in men and 2.9 % in women; clear-cell RCC is the most frequent histological type [7] . Up to 30 % of patients present with metastatic disease, and 30 % of patients develop metastases [8] . Based on ESMO guidelines [9] , three treatments can be recommended in first-line therapy of metastatic RCC patients with favorable or intermediate prognosis: bevacizumab (combined with interferon alpha), sunitinib, and pazopanib. All three drugs have been registered based on improvement of progression-free survival over either interferon alpha or placebo. Sorafenib and immunotherapy are alternative options when the other drugs cannot be safely given or in very selected cases. After first-line treatment with VEGFR-targeted therapy, both everolimus [5] and axitinib [10] are active and can be recommended. Both drugs have shown substantially improved progression-free survival over placebo (everolimus) or sorafenib (axitinib).
Shifting from bevacizumab to axitinib did not show activity in comparison with sorafenib (hazard ration (HR) for progression-free survival 1.147 (0.573-2.295) [10] ; HR for overall survival (bevacizumab vs. sunitinib) 0.821 (0.568-1.185) [11] ).
Efficacy of everolimus in patients who progressed on bevacizumab is unknown. Only one study, AVATOR, reported retrospective data on everolimus in routine use after prior firstline systemic therapy with bevacizumab ± IFN [12] . This study included 42 patients with good (28.1 %), intermediate (56.3 %), and poor (15.6 %) prognosis. First-line therapy was bevacizumab + IFN in 69 % of patients or bevacizumab only in 31 % of patients. Disease control rate was 59.5 % (overall response rate 9.5 %). During 8 months of treatment with everolimus, 52.3 % of patients had no disease progression. The authors concluded that this study provided encouraging results for the activity and safety profile of everolimus in second-line therapy of metastatic RCC after prior first-line therapy with bevacizumab.
Efficacy of temsirolimus in patients who progressed on bevacizumab is unknown. In a meta-analysis combining data from similarly designed studies of second-line treatment efficacy of temsirolimus, metastatic RCC patients who received a first-line TKI (sunitinib, sorafenib, or pazopanib) were included [13, 14] .
Our multicenter study CRAD001LRU02T prospectively evaluated the activity of everolimus in patients with metastatic RCC previously treated with bevacizumab ± IFN. The results support the role of mTOR as a potential therapeutic target in bevacizumab-resistant RCC. The 84 % disease control and 14 % overall response rates, along with the median progression-free survival of 11.5 months and 1-year overall survival of 81 %, indicate that everolimus is active in patients with progression despite previous treatment with bevacizumab. While cross-trial comparisons are challenging, the everolimus data of progression-free survival for the bevacizumab-refractory subgroup compare favorably with patient populations treated with everolimus in first-line (7.9 months) or sunitinib (10.7 months) [15] . Our data also support that potent inhibition of the mTOR after bevacizumab produces a more robust clinical effect than inhibition of the mTOR in patients previously treated with VEGFR-targeted therapy (median progression-free survival 5.4 months [16] , overall response rate 1.8 % [17] ).
The overall rate of grade 2 adverse events was low. The most common grade 2 adverse event was fatigue. Noninfectious pneumonitis, a potentially serious adverse event, was reported for three (8 %) patients receiving everolimus. mTOR inhibitors have immunosuppressive properties and may predispose patients to infections. However, there were no patients who experienced infections in the current trial.
In conclusion, everolimus demonstrated a favorable toxicity profile and promising anti-tumor activity as a second-line therapy in metastatic RCC patients previously treated with bevacizumab ± IFN. Larger trials are needed to better establish the role of everolimus in this subgroup of patients.
